A Randomized Prospective Study of Lumpectomy Margin Assessment with Use of MarginProbe in Patients with Nonpalpable Breast Malignancies. Gittleman et al - Ann Surg Oncol. 2014 May.
Vivamus molestie gravida turpis
Replacing Open Surgical Lumpectomy with a Percutaneous Approach for Small Breast Cancers Using the Intact (Breast Lesion Excision System) Percutaneous Excision Device - Schonholz ASBS Presentation 2016
TME IPEX Registry Investigator Steve Schonholz presents poster at 2016 Annual American Society of Breast Surgery meeting in Dallas.
Retrospective data analysis demonstrates feasibility of complete excision of smaller cancer lesions sized 4-12mm using the INTACT Breast Lesion Excision System (BLES). In 88% of cases complete excision was achieved, paving the way for minimally invasive management of small breast cancers.
Evaluation of Percutaneous Vacuum Assisted Intact Specimen Breast Biopsy Device for Ultrasound Visualized Breast Lesions: Underestimation rates and Long Term Follow-up Outcomes for High Risk Lesions and DCIS. Graham ASBS Presentation 2016.
TME IPEX Registry Investigator Cathy Graham presents poster on her experience with 469 patients at 2016 Annual American Society of Breast Surgery meeting in Dallas.
Upstage rates are markedly lower using BLES with U/S guidance (1.16%) than previously published data using large-gauge vacuum assisted core needle biopsy. Results suggest that high risk lesions can be managed with BLES reducing the need for surgical intervention.
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. Beitsch, Gittleman et al - PLoS One. 2015 Nov.
Spector N, Beitsch P, Gittleman M et al. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. PLoS ONE. 2015 Nov 10(11): e0142845. doi: 10.1371/journal.pone.0142845.